Fujita J, Miyakawa M, Tokuda H, Yoshida O
Gan. 1982 Apr;73(2):285-8.
An aromatic retinoic acid analog (Ro 10-9359) was given orally in combination with intraperitoneal administration of mitomycin C (MMC), in an attempt to reduce the toxicity and enhance the therapeutic effect. Male ACI/N rats were inoculated subcutaneously with BC50-TC cells, an established bladder carcinoma cell line of ACI/N rats. The chemotherapy was initiated at 16 days after the inoculation and continued for 4 weeks thereafter. Tumor growth was significantly inhibited in the rats given 100 mg/kg/week Ro 10-9359 or 0.3 mg/kg/twice a week MMC. Neither additive nor synergistic effect was apparent when these two drugs were given simultaneously. No effect was seen when 0.1 mg/kg/twice a week MMC was given alone or in combination with Ro 10-9359. MMC may suppress Ro 10-9359 activity directly or indirectly by affecting the responding cells. Therefore care should be taken when prescribing retinoids with MMC or possibly with other cytotoxic agents.
一种芳香维甲酸类似物（Ro 10-9359）通过口服给药，并联合腹腔注射丝裂霉素C（MMC），以试图降低毒性并增强治疗效果。雄性ACI/N大鼠皮下接种BC50-TC细胞，这是一种已建立的ACI/N大鼠膀胱癌细胞系。化疗在接种后16天开始，此后持续4周。给予100 mg/kg/周Ro 10-9359或0.3 mg/kg/每周两次MMC的大鼠肿瘤生长受到显著抑制。当这两种药物同时给药时，既没有相加作用也没有协同作用。单独给予0.1 mg/kg/每周两次MMC或与Ro 10-9359联合给药均未观察到效果。MMC可能通过影响反应细胞直接或间接抑制Ro 10-9359的活性。因此，在将维甲酸与MMC或可能与其他细胞毒性药物联合处方时应谨慎。
